Skip to main content
Torrent Pharmaceuticals Ltd. logo

Torrent Pharmaceuticals Ltd. — Investor Relations & Filings

Ticker · TORNTPHARM ISIN · INE685A01028 LEI · 335800NA6HK275RIJE13 BSE.NS Manufacturing
Filings indexed 1,760 across all filing types
Latest filing 2024-07-23 Investor Presentation
Country IN India
Listing BSE.NS TORNTPHARM

About Torrent Pharmaceuticals Ltd.

https://www.torrentpharma.com

Torrent Pharmaceuticals Ltd. is a research-driven organization focused on the development, manufacturing, and marketing of generic formulations. The company holds a significant position in therapeutic areas such as cardiovascular, central nervous system, gastrointestinal, diabetology, and anti-infective treatments. It has strategically expanded its portfolio into dermatology, nephrology, and pain management through targeted acquisitions. The firm operates across multiple international markets, supported by advanced research and development centers and manufacturing facilities that adhere to global regulatory standards. Its core operations prioritize chronic therapy leadership and the provision of high-quality healthcare solutions through a robust pipeline of generic and value-added medicines.

Recent filings

Filing Released Lang Actions
Investor Presentation.
Investor Presentation Classification · 95% confidence The document is a letter addressed to the stock exchanges (BSE and NSE) regarding a presentation to analysts on unaudited consolidated financial results for the quarter ended 30th June 2024. It includes summary revenue data for Q1 FY 2024-25. The document is titled as a presentation to analysts and contains financial highlights but is not a full quarterly report with detailed financial statements. The length is 1663 characters, which is short and consistent with a presentation or summary rather than a full interim report. Therefore, this document fits the category of an Investor Presentation (IP) rather than an Interim/Quarterly Report (IR) or Earnings Release (ER).
2024-07-23 English
Outcome of Board Meeting Dated 23-07-2024.
Regulatory Filings
2024-07-23 English
Investor Presentation
Investor Presentation Classification · 95% confidence The document is a letter addressed to the stock exchanges (BSE and NSE) regarding a presentation to analysts on unaudited consolidated financial results for the quarter ended June 30, 2024. It includes summary revenue data for Q1 FY 2024-25. The document is short (1663 characters) and explicitly states it is a presentation to analysts, not the full financial report itself. This matches the definition of an Investor Presentation (IP), which focuses on financials and strategy for investors. It is not an earnings release (ER) because it is a presentation, not just a key highlights announcement. It is not an Interim/Quarterly Report (IR) because it does not contain full financial statements or substantive financial data and analysis, only summary revenue figures. Therefore, the correct classification is Investor Presentation (IP).
2024-07-23 English
Outcome of Board Meeting
Regulatory Filings
2024-07-23 English
Results Q1 FY 2024-25.
Regulatory Filings
2024-07-23 English
Financial Result Updates
Regulatory Filings
2024-07-23 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.